|
coronary artery disease |
25 |
|
atrial fibrillation |
24 |
|
secondary prevention |
23 |
|
myocardial infarction |
21 |
|
chinese |
19 |
|
ischemic stroke |
16 |
|
cardiovascular magnetic resonance |
13 |
|
vitamin d |
13 |
|
hypertension |
12 |
|
recurrence |
12 |
|
heart failure |
11 |
|
risk prediction |
11 |
|
type 2 diabetes mellitus |
11 |
|
25-hydroxyvitamin d |
10 |
|
adipocyte |
10 |
|
b-type natriuretic peptide |
10 |
|
cardiac troponin |
10 |
|
exome chip |
10 |
|
fibroblast growth factor |
10 |
|
gastrointestinal haemorrhage |
10 |
|
genetic polymorphism |
10 |
|
lipocalin-2 |
10 |
|
mendelian randomization |
10 |
|
risk factor |
10 |
|
time in therapeutic range |
10 |
|
type 2 diabetes |
10 |
|
vitamin d-binding protein |
10 |
|
4d flow |
8 |
|
acute coronary syndrome |
8 |
|
direct flow |
8 |
|
hfpef |
8 |
|
intracranial hemorrhages |
8 |
|
intraventricular flow |
8 |
|
mortality |
8 |
|
residual volume |
8 |
|
trs 2°p |
8 |
|
cardiology |
7 |
|
carotid intima-media thickness |
7 |
|
asian |
6 |
|
cardiovascular death |
6 |
|
cardiovascular event |
6 |
|
dabigatran |
6 |
|
elderly |
6 |
|
general diabetes |
6 |
|
high sensitive troponin level |
6 |
|
non-st elevated myocardial infarction |
6 |
|
pathophysiological mechanism |
6 |
|
pr interval prolongation |
6 |
|
st segment elevation myocardial infarction |
6 |
|
statin intolerance |
6 |
|
timi grading system |
6 |
|
vascular function |
6 |
|
ventricular fibrillation |
6 |
|
adenosine triphosphate |
5 |
|
adult cardiology |
5 |
|
brugada syndrome |
5 |
|
chronic kidney disease |
5 |
|
clinical characteristics |
5 |
|
clinical pharmacology |
5 |
|
cohort studies |
5 |
|
coronary heart disease |
5 |
|
coronary intervention |
5 |
|
electronics |
5 |
|
genetic analysis |
5 |
|
ischaemic heart disease |
5 |
|
ischaemic stroke |
5 |
|
leadless pacemaker |
5 |
|
long qt syndrome |
5 |
|
mexiletine |
5 |
|
mitral valve |
5 |
|
monomorphic ventricular tachycardia |
5 |
|
outcomes |
5 |
|
peritoneal dialysis |
5 |
|
polymorphic ventricular tachycardia |
5 |
|
prognosis |
5 |
|
quinidine |
5 |
|
risk factors |
5 |
|
safety |
5 |
|
stress |
5 |
|
tricuspid valve insufficiency |
5 |
|
valvular heart disease |
5 |
|
2-hour ecg |
4 |
|
annonaceae |
4 |
|
anticholesteremic agents |
4 |
|
blood pressure variability |
4 |
|
bradycardia |
4 |
|
cardioprotective medications |
4 |
|
cardiovascular diseases/prevention and control |
4 |
|
cholesterol, ldl |
4 |
|
fluoroscopy |
4 |
|
heart rate |
4 |
|
hypercholesterolemia |
4 |
|
methamphetamine |
4 |
|
mitrephora monocarpa |
4 |
|
new species |
4 |
|
pregnancy |
4 |
|
pulmonary hypertension |
4 |
|
revascularization |
4 |
|
screening |
4 |
|
septal pacing |
4 |
|
sudden arrhythmic death |
4 |
|
symptoms |
4 |
|
technique |
4 |
|
thailand |
4 |
|
treatment inequality |
4 |
|
treatment outcome |
4 |
|
venous thromboembolism |
4 |
|
ventricular tachycardia, ventricular fibrillation |
4 |
|
atrial synchronous pacing |
3 |
|
biomarkers |
3 |
|
cardiac death |
3 |
|
cardiac rehabilitation |
3 |
|
cardiomyopathies |
3 |
|
cardiovascular diseases - mortality |
3 |
|
china |
3 |
|
dementia |
3 |
|
denervation |
3 |
|
exercise |
3 |
|
exercise therapy |
3 |
|
heart rate - physiology |
3 |
|
heart rate recovery |
3 |
|
kaplan-meier estimate |
3 |
|
left atrial thrombus |
3 |
|
models, animal |
3 |
|
myocardial infarction - mortality - physiopathology - rehabilitation |
3 |
|
neurology |
3 |
|
pacing |
3 |
|
vdd |
3 |
|
vvi |
3 |
|
accelerometry |
2 |
|
asia |
2 |
|
cardiovascular outcomes |
2 |
|
cause of death |
2 |
|
clinical effectiveness |
2 |
|
common carotid artery |
2 |
|
epidemiology |
2 |
|
feasibility |
2 |
|
hyperuricemia |
2 |
|
incidence |
2 |
|
left atrial spontaneous echo contrast |
2 |
|
pacemaker |
2 |
|
red cell distribution width |
2 |
|
review |
2 |
|
rheumatic |
2 |
|
spontaneous echo contrast |
2 |
|
subcutaneous implantable cardioverter-defibrillator |
2 |
|
thromboembolic event |
2 |
|
vibrations |
2 |
|
workload |
2 |
|
aortomitral continuity |
1 |
|
arrhythmogenic substrate |
1 |
|
cardiac anatomy |
1 |
|
catheter ablation |
1 |
|
clinical equipoise |
1 |
|
complications |
1 |
|
conduction system |
1 |
|
conus papillary muscle |
1 |
|
endocavitary structures |
1 |
|
his-purkinje system |
1 |
|
international |
1 |
|
lancisi bundle |
1 |
|
moderator band |
1 |
|
outflow tract |
1 |
|
papillary muscle |
1 |
|
premature ventricular complex |
1 |
|
premature ventricular contractions |
1 |
|
purkinje fiber |
1 |
|
right coronary cusp |
1 |
|
right ventricular outflow tract |
1 |
|
sick sinus syndrome |
1 |
|
sinus of valsalva |
1 |
|
sleep apnea |
1 |
|
survey |
1 |
|
ventricular arrhythmias |
1 |
|
ventricular tachycardia |
1 |
